1. Home
  2. MD vs GLPG Comparison

MD vs GLPG Comparison

Compare MD & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pediatrix Medical Group Inc.

MD

Pediatrix Medical Group Inc.

HOLD

Current Price

$20.80

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$28.83

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MD
GLPG
Founded
1979
1999
Country
United States
Belgium
Employees
N/A
704
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
MD
GLPG
Price
$20.80
$28.83
Analyst Decision
Hold
Buy
Analyst Count
4
2
Target Price
$20.00
$36.50
AVG Volume (30 Days)
728.5K
152.9K
Earning Date
05-05-2026
04-22-2026
Dividend Yield
N/A
N/A
EPS Growth
263.03
N/A
EPS
1.94
N/A
Revenue
$1,913,849,000.00
N/A
Revenue This Year
$3.72
N/A
Revenue Next Year
$2.62
N/A
P/E Ratio
$10.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.84
$22.59
52 Week High
$24.99
$37.78

Technical Indicators

Market Signals
Indicator
MD
GLPG
Relative Strength Index (RSI) 57.19 29.99
Support Level $20.72 $28.78
Resistance Level $21.98 $29.28
Average True Range (ATR) 0.61 0.78
MACD 0.18 -0.37
Stochastic Oscillator 76.58 2.13

Price Performance

Historical Comparison
MD
GLPG

About MD Pediatrix Medical Group Inc.

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: